MBX Biosciences, Inc. Common Stock (MBX)
Automate Your Wheel Strategy on MBX
With Tiblio's Option Bot, you can configure your own wheel strategy including MBX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MBX
- Rev/Share 0.0
- Book/Share 7.0459
- PB 1.6832
- Debt/Equity 0.0006
- CurrentRatio 23.3066
- ROIC -0.3456
- MktCap 396413028.0
- FreeCF/Share -2.0136
- PFCF -5.892
- PE -5.394
- Debt/Assets 0.0005
- DivYield 0
- ROE -0.441
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MBX | Citizens JMP | -- | Mkt Outperform | -- | $38 | April 10, 2025 |
| Initiation | MBX | Guggenheim | -- | Buy | -- | $44 | Oct. 8, 2024 |
| Initiation | MBX | Jefferies | -- | Buy | -- | $35 | Oct. 8, 2024 |
| Initiation | MBX | JP Morgan | -- | Overweight | -- | $30 | Oct. 8, 2024 |
| Initiation | MBX | Stifel | -- | Buy | -- | $40 | Oct. 8, 2024 |
News
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent …
Read More
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21.
Read More
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference.
Read More
MBX Biosciences to Participate in March Investor Conferences
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Monday, March 3, 2025Format: Podium Presentation and 1x1 meetingsTime: 10:30 a.m.
Read More
About MBX Biosciences, Inc. Common Stock (MBX)
- IPO Date 2000-01-14
- Website https://mbxbio.com
- Industry Biotechnology
- CEO Mr. Peter Kent Hawryluk MBA
- Employees 43